|
|
 | | | |
- close
- close
- close
- close
ARIAD Pharmaceuticals (ARIA) |
Stock Blog Hub
May 15
Comment
Ariad Pharmaceuticals, Inc. (ARIA) reported first quarter loss of 36 cents per share, wider than the year-ago loss of 25 cents per share but narrower than the Zacks Consensus Estimate of a loss of 37 cents per share.
First quarter revenues were...
StreetInsider.com
May 7
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Ariad+Pharma+%28ARIA%29+Posts+Narrower+than+Expected+Q1+Loss/8310665.html for the full story.
Market Intelligence Center
May 6
Comment
Ariad Pharmaceuticals (NASDAQ: ARIA) closed Friday's trading session at $17.07. In the past year, the stock has hit a 52-week low of $15.13 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $16.57 and...
Market Intelligence Center
Apr 30
Comment
Ariad Pharmaceuticals (NASDAQ: ARIA) closed Monday's trading session at $17.99. In the past year, the stock has hit a 52-week low of $15.13 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $17.53 and...
Sydney Morning Herald
Apr 24
Comment
Singer/songwriter Daniel Merriweather has pleaded guilty to crashing into a car while drunk before leaving the scene of the accident in Melbourne.
Stock Blog Hub
Apr 21
Comment
Ariad Pharmaceuticals, Inc. (ARIA) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant anaplastic lymphoba kinase (ALK) mutants resistant to Pfizer Inc.’s (PFE)...
Market Intelligence Center
Apr 18
Comment
Ariad Pharmaceuticals (NASDAQ: ARIA) closed Wednesday's trading session at $18.25. In the past year, the stock has hit a 52-week low of $14.35 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $17.33...
Market Intelligence Center
Apr 12
Comment
Ariad Pharmaceuticals (NASDAQ: ARIA) closed Thursday's trading session at $18.05. In the past year, the stock has hit a 52-week low of $14.10 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $17.72 and...
Benzinga
Apr 9
Comment
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of preclinical data on ponatinib (Iclusig™) at the American Association for Cancer Research (AACR) Annual Meeting 2013, in Washington. The study, “Ponatinib, a...
Market Intelligence Center
Apr 8
Comment
Ariad Pharmaceuticals (NASDAQ: ARIA) closed Friday's trading session at $16.88. In the past year, the stock has hit a 52-week low of $14.10 and 52-week high of $25.40. Ariad Pharmaceuticals (ARIA) stock has been showing support around $16.46 and...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSISAriad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.
References
Morningstar.com
| |||||||
